Document Detail


Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan.
MedLine Citation:
PMID:  22452375     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
So far, metastatic renal cell carcinoma has been one of the most treatment-resistant cancers. The extensive use of cytokines, such as interferon-α and interleukin-2, were carried out for metastatic renal cell carcinoma. However, significant advances in understanding the molecular mechanisms underlying renal cell carcinoma have led to the development of molecular target-based drugs, which were desperately awaited for a long time, and now two types of molecular target-based drugs are available. Two vascular endothelial growth factor receptor tyrosine kinase inhibitors and two mammalian target of rapamycin inhibitors have been approved and available in Japan. The molecular target-based drugs have unique and characteristic adverse events, whose profile are not well understood in Japanese patients, because most of the clinical trials were carried out in Europe and America. In contrast, immunotherapy is being reconsidered in the selection of more appropriate patients or as a combined treatment form with other drugs, because of few complete responses obtained and unexpected adverse events by molecular targeted treatments. We have several molecular targeted-drugs available at present and will have more, and we will actually use these drugs in various clinical settings, such as the presurgical setting, the adjuvant setting, sequential administration and combined administration, in addition to cytokines. Therefore, we need more elaborate studies to obtain the optimal treatment methods to maximize the effect of such agents to extend overall survival while maintaining quality of life of metastatic renal cell carcinoma patients. In this article, we reviewed the issues related to the current status of pharmacotherapy available for metastatic renal cell carcinoma.
Authors:
Yoshihiro Wada; Wataru Takahashi; Yoshiaki Kawano; Masatoshi Eto
Related Documents :
22674325 - Is it time for a metagenomic basis of therapeutics?
22556545 - Fungi from crude drugs.
22746205 - Supramolecular core-shell nanosilica@liposome nanocapsules for drug delivery.
22382795 - Development of a compatibility chart for intravenous y-site drug administration in a pe...
21826715 - Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models...
18765245 - Purification and characterization of a novel antinociceptive toxin from cobra venom (na...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of urology : official journal of the Japanese Urological Association     Volume:  19     ISSN:  1442-2042     ISO Abbreviation:  Int. J. Urol.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9440237     Medline TA:  Int J Urol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  284-95     Citation Subset:  IM    
Copyright Information:
© 2012 The Japanese Urological Association.
Affiliation:
Department of Urology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Persistent Atrial Fibrillation is Associated with a Poor Prognosis in Patients with Atrioventricular...
Next Document:  Cell Targeting Peptide Conjugation to siRNA Polyplexes for Effective Gene Silencing in Cardiomyocyte...